Evidence map›Paper›PMID 40998979›Full record

ArticleScientific reports2025

Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration.

Yue Chen, Xiaohuan Peng, Zuxi Feng, Li Zhang, Jun Bai, Yanhong Li, Lijuan Li, Liansheng Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yue ChenDepartment of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Xiaohuan PengDepartment of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Zuxi FengDepartment of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Li ZhangDepartment of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Jun BaiKey Laboratory of the Hematology of Gansu Province, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Yanhong LiKey Laboratory of the Hematology of Gansu Province, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China.
Lijuan LiDepartment of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China. doctorjuan@sina.com.
Liansheng ZhangDepartment of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, China. doctorzhanglsh@sina.com.

Funding

Cuiying Technology Innovation Program Project of Lanzhou University Second Hospital CY2024-MS-B13Gansu Province Key research and development Program Project 24YFFA046National Natural Science Foundation of China 82360029
6 · The paper itself

Abstract

We investigate the clinical significance of the peroxiredoxin (PRDX) family in multiple myeloma (MM) patients, focusing on its diagnostic and prognostic value, biological role and impact on the immune system. Using bioinformatics tools, such as CCLE, GEO, TCGA-MMRF, Kaplan-Meier plotter, enrichment and CIBERSORT analyses, we systematically characterized the expression levels, impact on survival and biological significance of PRDXs in MM. Bone marrow aspiration and clinical data were subsequently collected from MM patients to validate the findings related to PRDX2 from the databases. Finally, PRDX2 silencing in vitro modulated cell proliferation, immune infiltration and ferroptosis susceptibility. Compared with those in normal plasma cells, the expression levels of PRDX2/4/5/6 were significantly increased in myeloma cells. Furthermore, in relapsed MM cells, PRDX1/2/3/6 expression was significantly upregulated compared with that at baseline. Notably, PRDX2 was found to be highly expressed and associated with poor tumor characteristics, potentially contributing to disease progression and correlating with unfavourable prognosis. PRDX-related genes participate in various biological functions, influence metabolic pathways and may regulate ferroptosis and immune-related pathways in myeloma cells. This study is the first comprehensive analysis of the potential diagnostic and prognostic impact of the PRDXs family in MM, highlighting their significant associations with ferroptosis and the immune microenvironment. These findings provide a strong experimental and theoretical foundation for developing novel therapeutic strategies targeting ferroptosis and immunotherapy in MM.

Indexed as

Biomarkers, TumorFerroptosisMultiple MyelomaPeroxiredoxinsCell Line, TumorCell ProliferationComputational BiologyFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisTumor MicroenvironmentBiomarkers, TumorPeroxiredoxinsPRDX2 protein, humanBioinformatics analysisFerroptosisImmune infiltrationMultiple myelomaPRDX family

Identifiers

PMID40998979
PMCPMC12464289

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.